Advanced search
Publication Cover
Future Medicinal Chemistry Volume 5, 2013 - Issue 2
Submit an article Journal homepage
254
Views
0
CrossRef citations to date
0
Altmetric
Editorial

New Agents to Treat Lung Infection in Cystic Fibrosis: A Big Enough Leap?

Matthew Hurleya Division of Child Health, University of Nottingham, Nottingham, NG7 2UH, UK E-mail: [email protected]Correspondence[email protected]
View further author information
&
Alan Smythb Division of Child Health, University of Nottingham, UKView further author information
Pages 117-120 | Published online: 30 Jan 2013

References

  • Ramsey BW , DaviesJ, McElvaneyNGet al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365(18), 1663–1672 (2011).
  • Doring G , GulbinsE. Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease.Cell Microbiol.11(2), 208–216 (2009).
  • Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: Annual Data Report. Cystic Fibrosis Foundation, Bethesda, MD, USA (2011).
  • Langton-Hewer SC , SmythAR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev.4, CD004197 (2009).
  • Mayer-Hamblett N , KronmalRA, GibsonRLet al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr. Pulmonol. 47(2), 125–134 (2012).
  • Sanders DB , BittnerRCL, RosenfeldM, ReddingGJ, GossCH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.Pediatr. Pulmonol.46(4), 393–400 (2011).
  • Sanders DB , BittnerRC, RosenfeldM, HoffmanLR, ReddingGJ, GossCH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.Am. J. Respir. Crit. Care Med.182(5), 627–632 (2010).
  • Tunney MM , KlemER, FodorAAet al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 66(7), 579–584 (2011).
  • Stressmann FA , RogersGB, Van Der Gast CJ et al. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax67(10), 867–873 (2012).
  • Stressmann FA , RogersGB, MarshPet al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J. Cyst. Fibros. 10(5), 357–365 (2011).
  • Livermore DM . Discovery research: the scientific challenge of finding new antibiotics.J. Antimicrob. Chemother.66(9), 1941–1944 (2011).
  • Hurley MN , CamaraM, SmythAR. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur. Respir. J.40(4), 1014–1023 (2012).
  • Hurley MN , ForresterDL, SmythAR. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.Cochrane Database Syst. Rev. (10), CD008037 (2010).
  • Alibert-Franco S , PradinesB, MahamoudA, Davin-RegliA, PagèsJ. Efflux mechanism, an attractive target to combat multidrug resistant Plasmodium falciparum and Pseudomonas aeruginosa. Curr. Med. Chem.16(3), 301–317 (2009).
  • Goss CH , HornickDB, AitkenMLet al. Phase I pharmacokinetic and safety study of intravenous Ganite™ (gallium nitrate) in CF. Pediatr. Pulmonol. 47(S35), 303 (2012).
  • Wright A , HawkinsC, ÄnggardE, HarperD. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa. Curr. Opin. Otolaryngol.34(4), 349–357 (2009).
  • Guss AM , RoeselersG, NewtonILGet al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J. 5(1), 20–29 (2011).
  • De Boer K , VandemheenKL, TullisEet al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 66(8), 680–685 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.